GILD · 10-Q · 2026Q2 · Full report

Liquidity and Cash Position

GILEAD SCIENCES, INC. · 2026-08-06 · Importance 89 · Surprise 82 · Matches filing data

Cash and cash equivalents were $3.2 billion as of June 30, 2026. Operating cash flow increased to $6.1 billion for the first six months from $2.6 billion in the prior-year period, supported by lower tax payments, higher product-sale collections, the Lakefront collaboration payment and lower inventory spending. Investing cash use increased to $8.6 billion, primarily because of payments for the Arcellx, Tubulis and Ouro Medicines acquisitions. Financing cash use declined 62% to $1.9 billion because of 2026 debt-offering proceeds and lower share repurchases.

Key facts

• Net cash used in investing activities for the six months ended June 30, 2026: $(8,577) million. source
• Net cash provided by operating activities for the six months ended June 30, 2026: $6,117 million. source
• Cash and cash equivalents as of June 30, 2026: $3.2 billion. source
• Net cash used in financing activities for the six months ended June 30, 2026: $(1,895) million. source
• Net change in cash and cash equivalents for the six months ended June 30, 2026: $(4,385) million. source
• During the six months ended June 30, 2026, net cash provided by operating activities increased primarily due to lower income tax payments, collections on higher product sales, receipt of the Lakefront collaboration payment and lower inventory spend, partially offset by higher operating spend. source
• Net cash used in financing activities change for the six months ended June 30, 2026 was primarily due to proceeds from debt offerings in 2026, lower common stock repurchases, higher debt repayments and a contingent consideration payment made in 2026. source

Impact estimates